Web Date: September 22, 2017
Metallopeptide catalyst eases synthesis of antibody-drug conjugates
Antibody-drug conjugates are promising next-generation cancer therapies that can target and selectively kill malignant cells while sparing healthy ones. These conjugates—in which a drug is bound to an antibody through a small chemical linker—harness the antibody’s ability to recognize markers specific to cancer cells and bring the potent drugs to their intended site of action. But one conundrum that has plagued drug developers and scientists is how to consistently tether a drug onto a predictable . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society